Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Critical Care Antiarrhythmic Drugs Market: By Drug Class: Bovine, Human, Recombinant, Others; By End Use: Hospitals, Diagnostics, Others; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis; Competitive Landscape; Industry Events and Developments

Global Critical Care Antiarrhythmic Drugs Market Outlook

The global critical care antiarrhythmic drugs market reached a value of about USD 951.68 million in 2021. The market is further expected to grow at a CAGR of 5.62% in the forecast period of 2022-2027 to reach a value of around USD 1321.32 million by 2027.

 

Global Critical Care Antiarrhythmic Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

North America to be a Significant Regional Market for Critical Care Antiarrhythmic Drugs

North America represents a significant share of the critical care antiarrhythmic industry due to advancements in cutting-edge medical research and development (R&D) activities. The introduction of favourable reimbursement policies by governments and advanced health care infrastructure in the region is expected to surge the demand for critical care antiarrhythmic medicines and bolster the market growth in the forecast period. As several government-funded organisations, academic institutions, and private entities are intensely initiating clinical trials and drug development activities for effective treatment of complicated cardiac disorders, the market is poised to grow robustly in the coming years.

Europe is witnessing rapid growth owing to the increasing geriatric population with various health-related issues. The introduction of various favourable initiatives by governments to bolster the accessibility of healthcare is propelling the market growth. Further, the rising awareness regarding atrial fibrillation and associated heart conditions is anticipated to propel the regional market growth, which is estimated to significantly contribute to the growth of the overall industry.

 

Critical Care Antiarrhythmic Drugs: Market Segmentation

Critical care antiarrhythmic drugs refer to medications that are used in the treatment of arrhythmias during serious cardiovascular issues. They follow up on the heart's electrical conduction system trying to keep up the sinus beat. Calcium channel blockers, anti-adrenergic agents, antiarrhythmic agents, diuretic agents, and angiotensin-converting enzyme (ACE) inhibitors are some of the medications used to treat cardiac problems. Antiarrhythmic medications work by inhibiting aberrant cardiac rhythms caused by atrial flutter, atrial and ventricular fibrillation, and other irregular electrical activity of the heart.

 

Global Critical Care Antiarrhythmic Drugs Market By Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By drug class, the market is divided into:

  • Bovine
  • Human
  • Recombinant
  • Others

Based on end-use, the market includes:

  • Hospitals
  • Diagnostics
  • Others

The EMR report looks into the regional markets of critical care antiarrhythmic drugs like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Critical Care Antiarrhythmic Drugs Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increasing Regulatory Approvals of Novel Drug Formulations Boosting the Market Growth of Critical Care Antiarrhythmic Drugs

The growth of the critical care antiarrhythmic drugs industry can be attributed to the increasing approvals and active support for novel medication formulations for antiarrhythmic treatment by regulatory agencies. This, in turn, is encouraging major companies to innovate and bolster production, allowing them to meet the growing demand for effective cardiac treatments, hence driving the market growth. Moreover, the increasing prevalence of cardiovascular diseases in both developed and developing countries is expected to fuel the antiarrhythmic drugs industry in the forecast period. With the growing focus on heart health, the demand for critical care antiarrhythmic drugs is increasing, hence driving the market growth. The surging research and development (R&D) activities in drug discovery is anticipated to provide further impetus to the market growth in the coming years.

 

Key Industry Players in the Global Critical Care Antiarrhythmic Drugs Market

The report gives a detailed analysis of the following key players in the global critical care antiarrhythmic drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Pfizer
  • GlaxoSmithKline plc
  • Sanofi
  • Mylan N.V.
  • Upsher-Smith Laboratories LLC
  • Novartis AG
  • Mayne Pharma
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

REPORT FEATURES DETAILS
Base Year 2021
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Drug Class, End-use, Region
Breakup by Drug Class Bovine, Human, Recombinant, Others
Breakup by End Use Hospitals, Diagnostics, Others
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered Pfizer, GlaxoSmithKline plc, Sanofi, Mylan N.V., Upsher-Smith Laboratories LLC, Novartis AG, Mayne Pharma, Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Critical Care Antiarrhythmic Drugs Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Critical Care Antiarrhythmic Drugs Historical Market (2017-2021) 
    8.3    Global Critical Care Antiarrhythmic Drugs Market Forecast (2022-2027)
    8.4    Global Critical Care Antiarrhythmic Drugs Market by Drug Class
        8.4.1    Bovine
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    Human
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Recombinant
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2021)
            8.4.3.3    Forecast Trend (2022-2027)
        8.4.4    Others
    8.5    Global Critical Care Antiarrhythmic Drugs Market by End Use 
        8.5.1    Hospitals
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    Diagnostics 
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    Others 
    8.6    Global Critical Care Antiarrhythmic Drugs Market by Region
        8.6.1    Market Share
            8.6.1.1    North America
            8.6.1.2    Europe
            8.6.1.3    Asia Pacific
            8.6.1.4    Latin America
            8.6.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    Pfizer
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    GlaxoSmithKline plc
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Sanofi
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Mylan N.V.
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    Upsher-Smith Laboratories LLC
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    Novartis AG
            12.2.6.1    Company Overview
            12.2.6.2    Product Portfolio
            12.2.6.3    Demographic Reach and Achievements
            12.2.6.4    Certifications
        12.2.7    Mayne Pharma
            12.2.7.1    Company Overview
            12.2.7.2    Product Portfolio
            12.2.7.3    Demographic Reach and Achievements
            12.2.7.4    Certifications
        12.2.8    Others
13    Industry Events and Developments

 

List of Key Figures and Tables

1.    Global Critical Care Antiarrhythmic Drugs Market: Key Industry Highlights, 2017 and 2027
2.    Global Critical Care Antiarrhythmic Drugs Historical Market: Breakup by Drug Class (USD Million), 2017-2021
3.    Global Critical Care Antiarrhythmic Drugs Market Forecast: Breakup by Drug Class (USD Million), 2022-2027
4.    Global Critical Care Antiarrhythmic Drugs Historical Market: Breakup by End Use (USD Million), 2017-2021
5.    Global Critical Care Antiarrhythmic Drugs Market Forecast: Breakup by End Use (USD Million), 2022-2027
6.    Global Critical Care Antiarrhythmic Drugs Historical Market: Breakup by Region (USD Million), 2017-2021
7.    Global Critical Care Antiarrhythmic Drugs Market Forecast: Breakup by Region (USD Million), 2022-2027
8.    North America Critical Care Antiarrhythmic Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
9.    North America Critical Care Antiarrhythmic Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
10.    Europe Critical Care Antiarrhythmic Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
11.    Europe Critical Care Antiarrhythmic Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
12.    Asia Pacific Critical Care Antiarrhythmic Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
13.    Asia Pacific Critical Care Antiarrhythmic Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
14.    Latin America Critical Care Antiarrhythmic Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
15.    Latin America Critical Care Antiarrhythmic Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
16.    Middle East and Africa Critical Care Antiarrhythmic Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
17.    Middle East and Africa Critical Care Antiarrhythmic Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
18.    Global Critical Care Antiarrhythmic Drugs Market Structure

Key Questions Answered in the Report

In 2021, the global critical care antiarrhythmic drugs market attained a value of about USD 951.68 million.

The market is projected to grow at a CAGR of 5.62% between 2022 and 2027.

The market is estimated to witness a healthy growth in the forecast period of 2022-2027 to reach nearly USD 1321.32 million by 2027.

The market is being aided by the expansion of health care infrastructure, the increasing geriatric population, and the surging clinical trials and drug development activities for effective treatment of complicated cardiac disorders.

The increasing approval of novel drugs, the rising prevalence of cardiovascular diseases, and the surging research and development (R&D) activities in drug discovery are estimated to propel the growth of the market.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The major drug classes of critical care antiarrhythmic drugs are bovine, human, and recombinant, among others.

The significant disease types of antiarrhythmic drugs in the market are hospitals and diagnostics, among others.

The major players in the industry are Pfizer, GlaxoSmithKline plc, Sanofi, Mylan N.V., Upsher-Smith Laboratories LLC, Novartis AG, and Mayne Pharma, among others.

Analyst Review

The global critical care antiarrhythmic drugs market attained a value of about USD 951.68 million in 2021, driven by the increasing prevalence of cardiovascular diseases. Aided by the research and development (R&D) activities and favourable reimbursement policies, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 5.62%. The market is projected to reach nearly USD 1321.32 million by 2027.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on drug class, the critical care antiarrhythmic drugs industry is divided into bovine, human, and recombinant, among others. On the basis of end-use, the market is segmented into hospitals and diagnostics, among others. The major regional markets for critical care antiarrhythmic drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market are Pfizer, GlaxoSmithKline plc, Sanofi, Mylan N.V., Upsher-Smith Laboratories LLC, Novartis AG, and Mayne Pharma, among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER